If a panel of analysts are correct, the coming year will bring the reintroduction of Biogen-Idec's Tysabri, approval of Merck's human papilloma virus vaccine Gardasil and a continued stalemate over generic biologics. We asked top pharmaceutical analysts to weigh in on the events they think will move the market in 2006.
By Kate Rawson
The coming year will bring Food & Drug Administration approval of a first-ever cancer vaccine, the reintroduction of a withdrawn...
Join thousands of industry professionals who rely on Pink Sheet for daily insights
Already a subscriber?
Bristol Myers Squibb’s Opdivo and Merck's Welireg also could benefit from the delay in Medicare price negotiation process eligibility.
The Center for Biologics Evaluation and Research saw departures far outnumber new hires in the second and third quarters of FY 2025, before more than 100 people left July 14 after the reduction-in-force was finalized.
US FDA's cancer drugs division is feeling the effect of drug reviewer departures, despite efforts to keep them at the agency.
